Genitourinary Cancers

Daniel J. George, MD, Director, GU Oncology, Duke Cancer Institute, discusses critical phase III clinical trials in metastatic renal cell carcinoma.

Marijuana users had a small but statistically lower risk of bladder cancer compared with people who smoked tobacco or did not smoke.

The standard of care for metastatic renal cell carcinoma (RCC) prevailed in a randomized comparison of everolimus (Afinitor) and sunitinib (Sutent) as first-line therapy

Jeffrey A. Sosman, MD, Professor of Medicine, Director, Melanoma and Tumor Immunotherpay Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, discusses how immunotherapies work in patients with melanoma or renal cancer.

Patients with advanced renal cell carcinoma could experience a greater quality of life and the same treatment benefit with pazopanib as opposed to sunitinib.

Change may not always be pleasant, but it is inevitable, and nowhere has that been more evident recently than in US healthcare; however, for the physicians at Regional Urology in Shreveport, Louisiana, these changes are really just business as usual.

We should move away from directing therapy based on the primary site of malignancy and focus our efforts on inherent pathways common to the tumors, irrespective of the organ.

Nivolumab, the most advanced agent in the rapidly developing field of PD-1-targeting cancer immunotherapy, delivered durable clinical benefits across multiple solid tumor types.

Preoperative chemotherapy was not a predictor of postoperative complications, nor did it increase the length of hospital stays or surgical complications among patients undergoing radical cystectomy for muscle-invasive bladder cancer.

Current T staging for renal cell carcinoma does not capture the full picture of tumor volume, which data have shown to be more predictive of survival and recurrence in certain types of cancer.

An assay based on tumor genetics showed potential for stratifying risk in prostate cancer patients and aiding selection of men for active surveillance.

Thomas Hutson, DO, PharmD, discusses tivozanib for the treatment of advanced renal cell carcinoma (RCC).